LON:HIK - Hikma Pharmaceuticals Stock Price, Price Target & More

GBX 1,261 +42.50 (+3.49 %)

(As of 04/26/2018 04:00 PM ET)

Previous CloseGBX 1,261

Today's RangeGBX 1,206.50 - GBX 1,272

52-Week RangeGBX 814.20 - GBX 2,346

Volume554,896 shs

Average Volume822,138 shs

Market Capitalization£2.67 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

About Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segment's principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segment's principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segment's principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

SymbolLON:HIK

CUSIPN/A

Webwww.hikma.com

Phone+44-20-73992760

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins7.82%

Return on Equity5.69%

Return on Assets3.19%

Miscellaneous

EmployeesN/A

Outstanding Shares240,660,000

How to Become a New Pot Stock Millionaire

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Wednesday, March 14th. Shareholders of record on Thursday, April 5th will be paid a dividend of GBX 0.23 per share on Thursday, May 24th. This represents a yield of 1.47%. The ex-dividend date is Thursday, April 5th. This is an increase from Hikma Pharmaceuticals's previous dividend of $0.22. The official announcement can be accessed at this link. View Hikma Pharmaceuticals' Dividend History.

What price target have analysts set for HIK?

9 analysts have issued 1-year target prices for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 850 to GBX 1,310. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 1,107.44 in the next twelve months. View Analyst Ratings for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Some companies that are related to Hikma Pharmaceuticals include Valeant Pharmaceuticals International (VRX), Stada Arzneimittel (SAZ), Hikma Pharmaceuticals (HKMPY), MedReleaf (LEAF), OrganiGram (OGI), OrganiGram (OGRMF), International Cannabis (ICC), Cannabis Science (CBIS), Marijuana Co of America (MCOA), Science in Sport (SIS), Aequus Pharmaceuticals (AQS), Shield Therapeutics (STX), EVIO (EVIO), Evgen Pharma (EVG) and Venture Life Group (VLG).

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:

Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

Has Hikma Pharmaceuticals been receiving favorable news coverage?

News stories about HIK stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Hikma Pharmaceuticals earned a news sentiment score of 0.05 on Accern's scale. They also gave media stories about the company an impact score of 49.87 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,261.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £2.67 billion.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.

MarketBeat Community Rating for Hikma Pharmaceuticals (HIK)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		452 (Vote Outperform)
Underperform Votes:		260 (Vote Underperform)
Total Votes:		712

MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Hikma Pharmaceuticals (LON:HIK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

9 Wall Street analysts have issued ratings and price targets for Hikma Pharmaceuticals in the last 12 months. Their average twelve-month price target is GBX 1,107.44The high price target for HIK is GBX 1,310 and the low price target for HIK is GBX 850. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.11	2.11	2.11	2.20
Ratings Breakdown:	1 Sell Rating(s) 6 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	GBX 1,107.44	GBX 1,107.44	GBX 1,205	GBX 1,526.60

Hikma Pharmaceuticals (LON:HIK) Consensus Price Target History

Price Target History for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target
4/4/2018	Peel Hunt	Reiterated Rating	Hold
3/19/2018	Barclays	Reiterated Rating	Underweight	GBX 800 -> GBX 850
3/15/2018	Morgan Stanley	Boost Price Target	Equal weight	GBX 1,000 -> GBX 1,050
3/15/2018	Citigroup	Upgrade	Buy	GBX 1,250
3/15/2018	JPMorgan Chase	Boost Price Target	Neutral	GBX 1,000 -> GBX 1,050
3/15/2018	Jefferies Group	Upgrade	Hold	GBX 895 -> GBX 997
3/14/2018	Numis Securities	Initiated Coverage	Buy	GBX 1,300
11/9/2017	Stifel Nicolaus	Lower Price Target	Hold	GBX 1,320 -> GBX 1,000
8/22/2017	Goldman Sachs	Downgrade	Neutral	GBX 2,600 -> GBX 1,310
11/30/2016	AlphaValue	Reiterated Rating	Buy	GBX 2,431

(Data available from 4/26/2016 forward)

Hikma Pharmaceuticals (LON:HIK) Dividend History by Quarter

Announced	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/14/2018	$0.23	1.47%	4/5/2018	4/5/2018	5/24/2018
3/15/2017	€0.22	0.78%	4/6/2017	4/6/2017	5/25/2017
3/11/2015	€0.21	0.64%	4/16/2015	4/16/2015	5/21/2015

(Data available from 1/1/2013 forward)

Hikma Pharmaceuticals (LON HIK) Insider Trading and Institutional Ownership History

Insider Trading History for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON HIK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/19/2016	Ali Al-Husry	Insider	Buy	50,000	GBX 1,790	£895,000
12/16/2016	Mazen Darwazah	Insider	Buy	90,730	GBX 1,849	£1,677,597.70
12/12/2016	Ali Al-Husry	Insider	Buy	50,000	GBX 1,707	£853,500
12/9/2016	Ali Al-Husry	Insider	Buy	50,000	GBX 1,723	£861,500
12/6/2016	Ali Al-Husry	Insider	Buy	100,000	GBX 1,682	£1,682,000
12/5/2016	Ali Al-Husry	Insider	Buy	50,000	GBX 1,674	£837,000
12/2/2016	Mazen Darwazah	Insider	Buy	50,000	GBX 1,662	£831,000
12/1/2016	Mazen Darwazah	Insider	Buy	50,000	GBX 1,674	£837,000
11/30/2016	Said Darwazah	Insider	Buy	50,000	GBX 1,662	£831,000
9/28/2016	Said Darwazah	Insider	Buy	10,000	GBX 2,085	£208,500
9/27/2016	Ali Al-Husry	Insider	Buy	50,000	GBX 2,094	£1,047,000
9/26/2016	Said Darwazah	Insider	Buy	50,000	GBX 2,078	£1,039,000
9/23/2016	Ali Al-Husry	Insider	Buy	50,000	GBX 2,099	£1,049,500
9/21/2016	Ali Al-Husry	Insider	Buy	50,000	GBX 2,138	£1,069,000
9/16/2016	Al-Husry,Ali	Insider	Buy	50,000	GBX 2,119	£1,059,500
9/15/2016	Darwazah,Said	Insider	Buy	70,251	GBX 2,122	£1,490,726.22
9/8/2016	Darwazah,Mazen	Insider	Buy	150,000	GBX 2,162	£3,243,000
9/6/2016	Darwazah,Mazen	Insider	Buy	155,991	GBX 2,194	£3,422,442.54
8/31/2016	Al-Husry,Ali	Insider	Buy	140,000	GBX 2,150	£3,010,000
8/26/2016	Darwazah,Said	Insider	Buy	200,000	GBX 2,160	£4,320,000
6/24/2016	Darwazah,Mazen	Insider	Buy	150,000	GBX 2,200	£3,300,000
6/17/2016	Al-Husry,Ali	Insider	Buy	70,000	GBX 22	£15,400
5/9/2016	Darwazah,Said	Insider	Buy	17,440	GBX 2,228	£388,563.20
4/26/2016	Darwazah,Said	Insider	Buy	10,000	GBX 2,260	£226,000
4/25/2016	Darwazah,Said	Insider	Buy	10,000	GBX 2,324	£232,400
4/22/2016	Darwazah,Said	Insider	Buy	30,000	GBX 2,325	£697,500
4/20/2016	Darwazah,Said	Insider	Buy	30,000	GBX 2,271	£681,300
4/19/2016	Darwazah,Said	Insider	Buy	30,000	GBX 2,266	£679,800
4/11/2016	J. Castellani,John	Insider	Buy	2,500	GBX 2,103	£52,575
4/7/2016	Darwazah,Mazen	Insider	Buy	60,000	GBX 2,118	£1,270,800
4/5/2016	Darwazah,Said	Insider	Buy	30,000	GBX 2,055	£616,500
3/31/2016	Darwazah,Said	Insider	Buy	30,000	GBX 1,972	£591,600
3/24/2016	Butler,Pat	Insider	Buy	2,500	GBX 1,920	£48,000
3/21/2016	Pickering ,Robert	Insider	Buy	2,500	GBX 1,856	£46,400
8/27/2015	Kirby,Pamela	Insider	Buy	3,317	GBX 2,264	£75,096.88

(Data available from 1/1/2013 forward)

Hikma Pharmaceuticals (LON HIK) News Headlines

Source:

Date	Headline
	Hikma Pharmaceuticals Signs Licensing Agreement To Supply Enoxaparin www.morningstar.co.uk - April 24 at 8:25 AM
	Apotex next: Can Barry Sherman's company thrive again? www.theglobeandmail.com - April 21 at 8:26 AM
	BRIEF-Hikma Pharmaceuticals Says US Subsidiary Launches Dexrazoxane For Injection www.reuters.com - April 21 at 8:26 AM
	Hikma Pharmaceuticals (HIK) Earns "Neutral" Rating from JPMorgan Chase www.americanbankingnews.com - April 20 at 5:18 PM
	FTSE 250 movers: Hikma rallies; Countryside hit by Oaktree stake sale www.lse.co.uk - April 20 at 5:16 PM
	Hikma Pharmaceuticals (HIK) Price Target Lowered to GBX 1,410 at www.americanbankingnews.com - April 20 at 4:48 PM
	Hikma Subsidiary West-Ward Launches Dexrazoxane For Injection www.morningstar.co.uk - April 20 at 8:34 AM
	Hikma Pharma Launches Dexrazoxane For Injection www.nasdaq.com - April 20 at 8:34 AM
	Hikma Pharmaceuticals (HIK) Stock Rating Lowered by Morgan Stanley www.americanbankingnews.com - April 14 at 12:53 PM
	Estimating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK) finance.yahoo.com - April 13 at 8:31 AM
	Hikma Pharmaceuticals (HIK) Lowered to Neutral at Goldman Sachs www.americanbankingnews.com - April 10 at 8:37 AM
	Hikma Pharmaceuticals (HIK) Given Hold Rating at Peel Hunt www.americanbankingnews.com - April 4 at 12:31 PM
	Hikma Pharmaceuticals (HIK) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 4 at 5:31 AM
	Hikma Pharmaceuticals' (HIK) "Hold" Rating Reaffirmed at Peel Hunt www.americanbankingnews.com - April 3 at 10:30 PM
	Propeller Health Publishes Results From a Large Public Health Study on Asthma; Successfully Reduces the Burden of Asthma in Louisville finance.yahoo.com - April 3 at 8:32 AM
	Peel Hunt Reiterates "Hold" Rating for Hikma Pharmaceuticals (HIK) www.americanbankingnews.com - March 31 at 7:42 PM
	Hikma Pharmaceuticals' (HIK) Hold Rating Reaffirmed at Jefferies Group www.americanbankingnews.com - March 31 at 7:42 PM
	Hikma Pharmaceuticals (HIK) Given New GBX 865 Price Target at www.americanbankingnews.com - March 31 at 4:22 PM
	Hikma Pharmaceuticals (HIK) to Issue Dividend of $0.23 www.americanbankingnews.com - March 31 at 8:58 AM
	Hikma Pharmaceuticals (HIK) Lowered to Underperform at Jefferies Group www.americanbankingnews.com - March 29 at 5:16 PM
	Jefferies Group Reiterates Underperform Rating for Hikma Pharmaceuticals (HIK) www.americanbankingnews.com - March 27 at 10:22 PM
	Hikma Pharmaceuticals (HIK) Earns "Hold" Rating from Peel Hunt www.americanbankingnews.com - March 26 at 12:04 AM
	2 FTSE 250 pharma stocks I’d buy today and hold for another five years www.fool.co.uk - March 24 at 5:09 PM
	Hikma Pharmaceuticals (HIK) PT Lowered to GBX 1,160 www.americanbankingnews.com - March 24 at 12:54 PM
	Barclays Raises Hikma Pharmaceuticals (HIK) Price Target to GBX 850 www.americanbankingnews.com - March 19 at 6:46 PM
	Hikma Pharmaceuticals' (HIK) Buy Rating Reiterated at Numis Securities www.americanbankingnews.com - March 17 at 11:10 PM
	Jefferies Group Upgrades Hikma Pharmaceuticals (HIK) to Hold www.americanbankingnews.com - March 15 at 5:56 PM
	Hikma Pharmaceuticals (HIK) Upgraded at Citigroup www.americanbankingnews.com - March 15 at 5:04 PM
	Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at Morgan Stanley www.americanbankingnews.com - March 15 at 11:55 AM
	Hikma Pharmaceuticals (HIK) Price Target Increased to GBX 1,050 by Analysts at JPMorgan Chase & Co. www.americanbankingnews.com - March 15 at 9:09 AM
	Hikma Pharmaceuticals' (HKMPF) CEO Siggi Olafsson on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 15 at 8:26 AM
	[$$] Stocks to watch: PZ Cussons, Old Mutual, Dufry, Tesco, Hikma finance.yahoo.com - March 15 at 8:26 AM
	Drugmaker Hikma posts lower-than-expected 2017 profit - Reuters www.reuters.com - March 14 at 8:47 AM
	Drugmaker Hikma posts lower-than-expected 2017 profit finance.yahoo.com - March 14 at 8:47 AM
	Drugmaker Hikma sees more layoffs in generics business finance.yahoo.com - March 14 at 8:47 AM
	[$$] Stocks to watch: Dignity, Hikma, Conviviality, Bpost, Axel Springer finance.yahoo.com - March 14 at 8:47 AM
	Drugmaker Hikma's FY profit, revenue meet expectations; shares rise finance.yahoo.com - March 14 at 8:47 AM
	TOP NEWS: US FDA Upholds Advair Generic Issue With Hikma And Vectura www.morningstar.co.uk - March 12 at 10:04 AM
	FTSE 100 lags Europe on miners and energy, Just Eat goes cold finance.yahoo.com - March 12 at 10:03 AM
	Hikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - March 10 at 5:42 AM
	[$$] Stocks to watch: WPP, Burberry, Laird, Cobham, ITV, Ahold finance.yahoo.com - March 1 at 8:22 AM
	TOP NEWS: Hikma Appoints Sigurdur Olafsson As New Chief Executive www.morningstar.co.uk - February 20 at 5:40 PM
	UPDATE 1-Drugmaker Hikma names former Teva exec Olafsson as CEO; shares up www.reuters.com - February 20 at 5:40 PM
	Drugmaker Hikma Appoints Sigurdur Olafsson as CEO www.nytimes.com - February 20 at 5:40 PM
	[$$] Stocks to watch: InterContinental, HSBC, Dunelm, Hikma, Temenos finance.yahoo.com - February 20 at 8:24 AM
	Drugmaker Hikma names former Teva executive Olafsson as CEO; shares up finance.yahoo.com - February 20 at 8:24 AM
	[$$] Hikma appoints new CEO at ‘pivotal’ time finance.yahoo.com - February 20 at 8:24 AM
	Hikma Pharmaceuticals (HIK) Price Target Cut to GBX 1,180 www.americanbankingnews.com - February 18 at 12:10 AM
	Hikma Pharmaceuticals Plc (HIK) Given Average Recommendation of "Hold" by Brokerages www.americanbankingnews.com - February 13 at 5:40 AM
	Propeller Health Achieves ISO 13485 Medical Device Quality Certification finance.yahoo.com - February 8 at 8:16 AM

Hikma Pharmaceuticals (LON:HIK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Social activity is not available for this stock.

Financials are not available for this stock.

Hikma Pharmaceuticals (LON HIK) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff